Regulation of INS (3456) P4 Signaling by a Reversible Kinase/Phosphatase and Methods and Compositions Related Thereto
Description of Invention:
Receptor-dependent changes in Ins(3,4,5,6)P4 levels is a topic of general biological significance, since this regulates the activities of chloride channels that in turn regulate salt and fluid and mucus secretion from epithelial cells, cell volume homeostasis, and electrical excitability in neurons and smooth muscle.
The NIH announces new treatment methods for asthma, bronchitis and cystic fibrosis. The treatments consist of either increasing or decreasing the activity of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase in a patient, thereby controlling Ins(3,4,5,6)P4-signaling which in turn affects the chloride channels, ultimately regulating salt, fluid and mucus secretion. This modulation of inositol 1,3,4,5,6 pentakisphosphate 1-phosphatase is accomplished by either pharmacological or genetic intervention.
Inventors:
Stephen Shears (NIEHS) et al.
Patent Status:
DHHS Reference No. E-105-2002/0 --
U.S. Patent Application No. 10/508,363 filed 16 Sep 2004, claiming priority to 18 Mar 2002
Licensing Status: In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
Portfolios: Internal Medicine
Internal Medicine-Therapeutics
For Additional Information Please Contact: Charlene A. Sydnor Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4689
Email: sydnorc@mail.nih.gov
Fax: 301/402-0220
